The activity of N-hexanoyl-D-erythro-sphingosine, a C6-ceramide against angiogenesis was tested in vitro and in vivo. The effect of ceramide in inhibiting MCF-7 cancer cells was also determined. The aim of this study was to potentiate the effect of ceramide as anti-angiogenic compound that can regulate tumor induced angiogenesis.C6-ceramide inhibited vascular endothelial growth factor (VEGF)-in...

Background: Galectin, an animal lectin that recognizes b-galactosides of glycoconjugates, is involved in multiple biological functions such as cell growth, differentiation, apoptosis, signal transduction and angiogenesis. Overexpression of galectin-3 was observed in different tumors which was related to pro-angiogenic activity. In addition, galectin-3 is intensely expressed in corpus luteum (CL...

The objective of this research was to test the in vitro anti-angiogenic activity of auraptene, a coumarin from citrus peel oil. We tested the ability of auraptene to inhibit in vitro angiogenesis using vascular endothelial growth factor (VEGF)-induced human umbilical endothelial cells (HUVEC) growth stimulation. Auraptene was applied at concentrations between 0 μM and 1μM to HUVEC in the presen...

In 1971, Judah Folkman developed the concept of “anti-angiogenesis” as a potential treatment of cancer due to “the prevention of new vessel sprouts from penetrating into early tumor implant” [1]. Beginning in the 1980’s, the industry exploited the field of anti-angiogenesis for creating new therapeutic molecules in angiogenesisdependent diseases. In 2004, the first anti-angiogenic drug, bevaciz...

Pathological vessel growth harms vision and may finally lead to loss. Anti-angiogenic gene therapy with viral vectors for ocular neovascularization has shown great promise in preclinical studies. Most of the studies have been conducted different adeno-associated serotype vectors. In addition, adeno- lentivirus used. Therapy targeted towards blocking vascular endothelial factors or other pro-ang...

Despite the approval of several anti-angiogenic therapies, clinical results remain unsatisfactory, and transient benefits are followed by rapid tumor recurrence. Here, we demonstrate potent anti-angiogenic efficacy of the multi-kinase inhibitors nintedanib and sunitinib in a mouse model of breast cancer. However, after an initial regression, tumors resume growth in the absence of active tumor a...